POLICY
China's AI pharma sector converges on policy, capital, and clinical milestone
Three simultaneous developments — a new Five-Year Plan, a $2.9 billion Series A record, and the world's first AI-designed drug entering Phase III — mark a structural shift in China's pharmaceutical industry.